Other languages Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-13 EDT			5-day change	1st Jan Change
2.16 ^USD	0.00%		+7.46%	+23.42%

05-09	Transcript : Plus Therapeutics, Inc. - Special Call
05-09	Plus Therapeutics, Inc. announced that it has received $7.262078 million in funding from Aigh Capital Management, LLC	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	03-25
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	03-11
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	11-20
Top Premarket Gainers	11-03
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	23-10-31
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	23-10-31
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-31
Plus Therapeutics, Inc. authorizes a Buyback Plan.	23-10-30
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	23-10-10
Sector Update: Health Care Stocks Slipping Late Friday8 Afternoon	23-09-08
Sector Update: Health Care Stocks Slipping Friday Afternoon	23-09-08
Sector Update: Health Care	23-09-08
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	23-09-08
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	23-09-08
Top Premarket Gainers	23-09-08
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase	23-09-05
Plus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14
Plus Therapeutics Says Leptomeningeal Metastases Phase 1 Trial of Rhenium Obisbemeda Showed Lower Tumor Cell Counts	23-08-11
Plus Therapeutics, Inc. Appoints Pius Maliakal as Vice President of Clinical Operations	23-07-27

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Plus Therapeutics, Inc.

Equities

PSTV

US72941H5090

Other languages

Filters